The work carried out by the authors on calcium and the cardiovascular risk is of primary importance.¹ We thank the authors for questions and comments on the Strontium ranelate Efficacy in Knee OsteoarthrItis trIAl (SEKOIA) study, safety being a primary concern for us.²

The number of emergent adverse events reported in the SEKOIA study was similar in the three treatment groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups, as well as the number of serious emergent adverse events: 17.0%, 16.5% and 17.4%, respectively. The adverse reactions …